"10.1371_journal.pone.0030538","plos one","2012-03-02T00:00:00Z","Aparna Talekar; Antonello Pessi; Fraser Glickman; Uttara Sengupta; Thomas Briese; Michael A Whitt; Cyrille Mathieu; Branka Horvat; Anne Moscona; Matteo Porotto","Departments of Pediatrics, Microbiology and Immunology, Weill Medical College, Cornell University, New York, New York, United States of America; PeptiPharma, Pomezia, Italy; High Throughput Screening Resource Center, The Rockefeller University, New York, New York, United States of America; Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, New York, United States of America; Department of Microbiology, Immunology and Biochemistry, Health Science Center, The University of Tennessee, Memphis, Tennessee, United States of America; INSERM, U758, Ecole Normale Sup√©rieure de Lyon, Lyon, France; IFR128 BioSciences Lyon-Gerland Lyon-Sud, University of Lyon 1, Lyon, France","Conceived and designed the experiments: AT AM FG MP BH. Performed the experiments: AT MP FG CM US. Analyzed the data: AM AT FG AP MP. Contributed reagents/materials/analysis tools: TB MAT. Wrote the paper: AM MP AP BH MAW.","Dr. Pessi is CEO of Peptipharma. This company has an invested interest in developing antiviral peptides using cholesterol tagging. This technology is not used in this manuscript therefore there are no competing or conflict of interests. This therefore does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","03","Aparna Talekar","AT",10,TRUE,5,5,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
